Ogden Christopher 4
4 · CytomX Therapeutics, Inc. · Filed Aug 22, 2024
Insider Transaction Report
Form 4
Ogden Christopher
Chief Financial Officer
Transactions
- Sale
Common Stock
2024-08-20$1.23/sh−1,984$2,439→ 108,077 total - Exercise/Conversion
Common Stock
2024-08-20+6,875→ 110,061 total - Exercise/Conversion
Performance Stock Units (PSUs)
2024-08-20−6,875→ 0 total→ Common Stock (6,875 underlying)
Footnotes (4)
- [F1]Represents vesting of a Performance Stock Unit ("PSU") award initially granted on August 10, 2022.
- [F2]Includes 77,810 restricted stock units.
- [F3]The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs reported herein.
- [F4]Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone.